Key clinical point: Lasmiditan is associated with temporarily worsened driving performance.
Major finding: Compared with placebo, lasmiditan is associated with impaired driving at 1.5 hours after dosing.
Study details: Two randomized, controlled, crossover studies that included 158 healthy participants.
Disclosures: Eli Lilly, the developer of lasmiditan, sponsored the studies. Several of the investigators are employees of the company.
Pearlman E et al. AHS 2019, Abstract IOR06.